RNAi Technology Market

SKU: DMBT2276 | Last Updated On: Oct 28 2022 | Available Formats

RNAi Technology Market Expected to reach a high CAGR of 11.30% by 2029

RNAi Technology Market is segmented By Application (Drug discovery and Development, Therapeutics, Drug Delivery, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 RNAi Technology Market size was valued at USD 1,126.20 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 11.30% over the forecast period 2022 to 2029.

 RNAi Technology Market - Strategic Insights



Market CAGR


Segments Covered

By Application, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

RNA interference (RNAi) is a technology used to treat cancer and other diseases by post-transcriptional silencing of genes by small nucleic acid fragments. This technology helps provide target specificity to proteins lacking the enzymatic pocket necessary for binding. RNAi has a significant impact on the speed, ease, and specificity with which the loss of gene function analysis can be made in mammalian cells and animal models. This technology can validate the target genes and functionally assess relevant disease genes. Hence, leading to the development of effective therapeutics.

As per DataM Intelligence, RNAi Technology Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global RNAi Technology Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. RNAi Technology Market in the United States and Canada produces the utmost share. Whereas the European RNAi Technology Market is projected to continue its presence globally during the period of 2022- 2029.

Market Dynamics

The rising R&D initiatives, rising genetic and metabolic disorders and increasing applications in molecular diagnostics such as cancer are expected to increase market growth during forecast period.

Rising genetic and metabolic disorders and increasing applications in molecular diagnostics (Cancer) are expected to drive market growth.

The global RNAi technology market growth is driven by several factors, such as rising genetic and metabolic disorders, increasing molecular diagnostics applications, cancer, and growing research & development activities for drug discovery.

Increasing incidences of cancer are driving the demand for enhanced molecular diagnostics. According to the National Cancer Institute estimations, around 1,735,350 new cancer cases were diagnosed in 2019 in the United States, and about 609,640 people were predicted to die from the diseases. Chemotherapy, despite being an effective cancer treatment, does not differentiate between normal and cancerous cells. The therapy causes harm to the normal cells that are close to the cancerous cells. Hence, the demand for RNAi technology for cancer therapy is estimated to grow significantly over the forecast period.

RNAi drives the pharmaceutical domain's growth with a robust pipeline of drug candidates based on this principle. For instance, in July 2019, Dicerna Pharmaceuticals has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA). The goal is to receive approval to launch a first-in-human Phase I/II clinical trial of DCR-A1AT to treat alpha-1 antitrypsin (A1AT) deficiency-associated liver disease. Dicerna focuses on what is called RNA interference or RNAi. The technology turns off RNA, which results in halting the production of disease-causing proteins.

Stringent FDA regulations and RNA is inherently unstable, potentially immunogenic are expected to hamper the market growth.

The market growth is restrained by stringent government policies, regulations, and FDA approvals. RNA is potentially immunogenic and inherently unstable, which hinders the research and development of drugs.

Industry Analysis

The global RNAi technology market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Pipeline Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Therapeutics segment is expected to hold the largest market share in global RNAi technology market

The market is segmented into drug discovery & development, therapeutics, drug delivery, and others based on application. Therapeutics is the major growing sector due to the increased demand for cancer and liver disorders. The Therapeutics market is further segmented into oncology, liver disorders, neurological disorders, respiratory disorders, autoimmune disorders, ocular disorders, etc. The oncology segment accounted for the largest market share in the RNAi technology market due to the growing demand for better diagnostic and treatment methods for rising different cancer cases. According to the World Health Organization, cancer is the second leading cause of death globally and responsible for 8.8 million deaths in a year. Nearly one in six deaths can be attributed to cancer worldwide. The number of new cases is expected to rise by about 70% over the next two decades. Recent advancements, such as the development of small interfering RNA (siRNA) tolerant to nucleases and the development of non-viral vectors, such as cationic liposomes and nanoparticles, can overcome this obstacle in the clinical use of RNAi-based therapeutics in the treatment of cancer. This technology provides a targeted approach for cancer therapy which is desirable to receive precise treatment.

Geographical Analysis

North America region holds the largest market share in the global RNAi technology market

By region, the global RNAi technology market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global RNAi Technology market due to high technological advancement for developing RNAi technology. There is a large number of companies conducting research and development for RNAi technology. North America is dominating the global RNAi technology market accounting for the largest market share, owing to the increasing prevalence of cancer, respiratory disorders, liver disorders, and others in this region. According to the National Cancer Institute, an estimated 15,270 children and adolescents between 0 and 19 in the United States were diagnosed with cancer, out of these, 1,790 died from the disease. Also, leading companies in the United States involved in developing novel therapies for cancer treatment further boost its growth.

For instance, on July 23rd, 2019, Alnylam Pharmaceuticals, Inc., the leading RNA interference (RNAi) therapeutics company, announced the Health Canada approval and immediate availability of ONPATTRO (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. ONPATTRO is the only treatment in Canada for all polyneuropathy stages associated with hATTR amyloidosis, a progressive, debilitating, chronic, and often fatal disease. ONPATTRO is based on Nobel Prize-winning science and is the first-ever RNAi therapeutic to be approved in Canada.

On the other hand, the Asia-Pacific RNAi technology market is estimated to grow at the highest CAGR over the forecast period, owing to growing awareness among people about the risks related to these diseases and increasing funding by private and government organizations for the research & development of targeted drugs and therapies.

Competitive Landscape

The global RNAi technology market is highly fragmented with a large number of global & local players. Some of the market's major players include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., RXI Pharmaceuticals, Filmtec Corporation, Benitec Biopharma Ltd Quark Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Silence Therapeutics, Invitrogen, Qiagen, among others.

The key players are adopting various growth strategies such as expansion, mergers & acquisitions, partnerships, product launches, and collaborations, contributing to the growth of the RNAi Technology market globally. For instance,

In April 2019, Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. collaborated to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS) in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise. It will build on Alnylam's recent preclinical data showing potent and highly durable RNAi therapeutics delivery to achieve target gene silencing in the eye and CNS. The collaboration will also benefit from Regeneron's industry-leading VelociSuite technologies and capabilities from the Regeneron Genetics Center (RGC).

In March 2019, Tropic Biosciences, a pioneering agricultural biotechnology company dedicated to developing high-performing tropical crops, launched its proprietary GEiGS technology (Gene Editing induced Gene Silencing) computational platform that enables its application, GEiGS-BioCompute. GEiGS builds upon available gene-editing tools (e.g., CRISPR, TALEN) to edit existing RNAi genes and direct their silencing functions towards new targets, including insects, viruses, fungi, or even a plant’s genes.

Global RNAi Technology Market – Key Companies to Watch

Ionis Pharmaceuticals, Inc. 

Overview: Ionis Pharmaceuticals is biotechnology company that was founded in 1989 and is headquartered in Carlsbad, California. It discovers and develops RNA targeted therapeutics. There are total 3 approved medicines those are: Nusinersen, Inotersen, and Volanesorsen.

Product Portfolio:

Danvatirsen: Also known as IONIS STAT3-2.5 AND AZD9150. It is an antisense medicine that is developed to minimize the production of activator of STAT 3 to help in treating patients with cancer.

Key Developments: In Jan 2022, Ionis Pharmaceuticals, Inc. announced about the designing of phase 2 trial by their partner Roche to assess tominersen in Huntington’s disease.

The global RNAi technology market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.


Frequently Asked Questions

What is the Projected CAGR value of the RNAi Technology Market?

RNAi Technology Market is expected to grow at a CAGR of 11.30% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the RNAi Technology Market during 2022-2029.

Which is the fastest growing region in the RNAi Technology Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Drug Discovery Informatics Market

Drug Delivery Devices Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!